About 32 results found for searched term "PLK" (0.107 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2860 | MLN0905 | PLK |
| PLK1 Inhibitor | ||
| MLN0905 is an orally active, potent PLK1 inhibitor with an IC50 of 2 nM. can be used in tumor related studies. | ||
| M41580 | PLK1-IN-6 | PLK |
| PLK1-IN-6 is a potent and selective PLK1 inhibitor, with an IC50 of 0.45 nM. | ||
| M41581 | PLK1-IN-5 | PLK |
| PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. | ||
| M1672 | BI 2536 | PLK |
| BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. | ||
| M1678 | BI 6727 | PLK |
| Volasertib | ||
| BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk1) with an IC50 of 0 .87 nM. | ||
| M1719 | GSK461364 | PLK |
| GSK461364A | ||
| GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. | ||
| M2211 | Rigosertib sodium | PLK |
| ON-01910 sodium; CAS# 592542-60-4 | ||
| Rigosertib sodium is a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K). | ||
| M2741 | GW843682X | PLK |
| GW843682 | ||
| GW 843682X is a PLK inhibitor for PLK1 and PLK3 with IC50 of 2.2 nM and 9.1 nM, respectively. | ||
| M2983 | Ro3280 | PLK |
| Ro5203280 | ||
| RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM. | ||
| M3198 | TAK-960 | PLK |
| TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM. | ||
| M3293 | HMN-214 | PLK |
| IVX-214 | ||
| HMN-214 is a procompound of HMN-176, which alters the cellular spatial orientation of Plk1. | ||
| M3552 | PHA-680632 | Aurora Kinase |
| PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3. | ||
| M6576 | Centrinone | PLK |
| Centrinone is a high affinity and selective PLK4 inhibitor. | ||
| M6577 | Centrinone B | PLK |
| Centrinone B is a high affinity and selective PLK4 inhibitor. | ||
| M6649 | CZC-25146 | LRRK2 |
| CZC25146 | ||
| CZC 25146 is a potent and orally active LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. | ||
| M7271 | SBE13 hydrochloride | PLK |
| SBE13 HCl | ||
| SBE13 hydrochloride is a potent and selective PLK1 inhibitor. | ||
| M7350 | TAK 960 hydrochloride | PLK |
| TAK 960 hydrochloride is a potent PLK1 inhibitor (IC50 values are 0.8, 16.9 and 50.2 nM for PLK1, PLK2 and PLK3 respectively). Exhibits >20-fold selectivity for PLK1 over FAK, MLCK and FES, and has minimal activity against a panel of 282 other kinases. | ||
| M7645 | BTO-1 | PLK |
| BTO-1 is a polo-like kinase (Plk) inhibitor. | ||
| M8358 | Poloxin | PLK |
| Poloxin is a non-ATP competitive Polo-like Kinase 1 (Plk1) inhibitor that targets the polo-box domain. | ||
| M9250 | HMN-176 | PLK |
| HMN-176 inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization. | ||
| M9307 | TC-S 7005 | PLK |
| ABM-9921 | ||
| TC-S 7005 is a potent and selective polo-like kinase 2 (PLK2) inhibitor (IC50 = 4 nM). | ||
| M13718 | Onvansertib | PLK |
| PCM-075; NMS-1286937; NMS-P937 | ||
| Onvansertib (PCM-075, NMS-1286937, NMS-P937) is a first-in-class, third-generation, oral, highly selective PLK1 inhibitor that induces tumor cell arrest in the G2/M phase and triggers apoptosis. It has a median IC50=136nM against a variety of CRC cell lines and inhibits xenograft models such as HT-29, HCT-116, and Colo-205 well. | ||
| M13721 | TAK-960 dihydrochloride | PLK |
| TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. | ||
| M20605 | CFI-400945 | PLK |
| CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM. | ||
| M27875 | CFI-400437 | PLK |
| CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM). | ||
| M28838 | Poloxime | PLK |
| Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity. | ||
| M29436 | AAPK-25 | Aurora Kinase |
| AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. | ||
| M30051 | Cyclapolin 9 | PLK |
| Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC50 of 500 nM. Cyclapolin 9 is inactive against other kinases. | ||
| M30482 | Poloppin | PLK |
| Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors. | ||
| M31203 | ON1231320 | PLK |
| ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 µM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. | ||
| M31250 | HPN-01 | IκB/IKK |
| HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2. | ||
| M38942 | Dihydrobaicalein | PLK |
| Dihydrobaicalein is a PLK1 Inhibitor with an IC50 of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
